Literature DB >> 24795354

Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade.

Ines Pires da Silva1, Anne Gallois, Sonia Jimenez-Baranda, Shaukat Khan, Ana C Anderson, Vijay K Kuchroo, Iman Osman, Nina Bhardwaj.   

Abstract

The immunoregulatory protein T-cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates T-cell exhaustion and contributes to the suppression of immune responses in both viral infections and tumors. Tim-3 blockade reverses the exhausted phenotype of CD4+ and CD8+ T cells in several chronic diseases, including melanoma. Interestingly, natural killer (NK) cells constitutively express Tim-3; however, the role of Tim-3 in modulating the function of these innate effector cells remains unclear, particularly in human diseases. In this study, we compared the function of Tim-3 in NK cells from healthy donors and patients with metastatic melanoma. NK cells from the latter were functionally impaired/exhausted, and Tim-3 blockade reversed this exhausted phenotype. Moreover, Tim-3 expression levels were correlated with the stage of the disease and poor prognostic factors. These data indicate that Tim-3 can function as an NK-cell exhaustion marker in advanced melanoma and support the development of Tim-3-targeted therapies to restore antitumor immunity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24795354      PMCID: PMC4046278          DOI: 10.1158/2326-6066.CIR-13-0171

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  38 in total

1.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

Review 2.  T cell exhaustion.

Authors:  E John Wherry
Journal:  Nat Immunol       Date:  2011-06       Impact factor: 25.606

3.  Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma.

Authors:  Sophia Platonova; Julien Cherfils-Vicini; Diane Damotte; Lucile Crozet; Vincent Vieillard; Pierre Validire; Pascale André; Marie-Caroline Dieu-Nosjean; Marco Alifano; Jean-François Régnard; Wolf-Herman Fridman; Catherine Sautès-Fridman; Isabelle Cremer
Journal:  Cancer Res       Date:  2011-06-27       Impact factor: 12.701

4.  Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas.

Authors:  Muhammad Baghdadi; Hiroko Nagao; Hironori Yoshiyama; Hisaya Akiba; Hideo Yagita; Hirotoshi Dosaka-Akita; Masahisa Jinushi
Journal:  Cancer Immunol Immunother       Date:  2012-11-10       Impact factor: 6.968

5.  Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients.

Authors:  Lukas Baitsch; Petra Baumgaertner; Estelle Devêvre; Sunil K Raghav; Amandine Legat; Leticia Barba; Sébastien Wieckowski; Hanifa Bouzourene; Bart Deplancke; Pedro Romero; Nathalie Rufer; Daniel E Speiser
Journal:  J Clin Invest       Date:  2011-05-09       Impact factor: 14.808

6.  Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity.

Authors:  Emilie Mamessier; Aude Sylvain; Marie-Laure Thibult; Gilles Houvenaeghel; Jocelyne Jacquemier; Rémy Castellano; Anthony Gonçalves; Pascale André; François Romagné; Gilles Thibault; Patrice Viens; Daniel Birnbaum; François Bertucci; Alessandro Moretta; Daniel Olive
Journal:  J Clin Invest       Date:  2011-08-15       Impact factor: 14.808

7.  Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells.

Authors:  Saar Gill; Adrianne E Vasey; Alysha De Souza; Jeanette Baker; Aaron T Smith; Holbrook E Kohrt; Mareike Florek; Kenneth D Gibbs; Keri Tate; David S Ritchie; Robert S Negrin
Journal:  Blood       Date:  2012-04-27       Impact factor: 22.113

8.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

9.  Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9.

Authors:  Michelle K Gleason; Todd R Lenvik; Valarie McCullar; Martin Felices; M Shea O'Brien; Sarah A Cooley; Michael R Verneris; Frank Cichocki; Carol J Holman; Angela Panoskaltsis-Mortari; Toshiro Niki; Mitsuomi Hirashima; Bruce R Blazar; Jeffrey S Miller
Journal:  Blood       Date:  2012-02-08       Impact factor: 22.113

10.  Cancer statistics, 2013.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2013-01-17       Impact factor: 508.702

View more
  154 in total

1.  Accumulation of Cytotoxic CD16+ NK Cells in Simian Immunodeficiency Virus-Infected Lymph Nodes Associated with In Situ Differentiation and Functional Anergy.

Authors:  Jamie L Schafer; Haiying Li; Tristan I Evans; Jacob D Estes; R Keith Reeves
Journal:  J Virol       Date:  2015-04-22       Impact factor: 5.103

Review 2.  Strategies to enhance NK cell function for the treatment of tumors and infections.

Authors:  Jacquelyn Freund-Brown; Leilani Chirino; Taku Kambayashi
Journal:  Crit Rev Immunol       Date:  2018       Impact factor: 2.214

3.  Reversal of natural killer cell exhaustion by TIM-3 blockade.

Authors:  Anne Gallois; Ines Silva; Iman Osman; Nina Bhardwaj
Journal:  Oncoimmunology       Date:  2015-01-07       Impact factor: 8.110

Review 4.  Exploring the NK cell platform for cancer immunotherapy.

Authors:  Jacob A Myers; Jeffrey S Miller
Journal:  Nat Rev Clin Oncol       Date:  2020-09-15       Impact factor: 66.675

5.  PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients.

Authors:  Fernando Concha-Benavente; Benjamin Kansy; Jessica Moskovitz; Jennifer Moy; Uma Chandran; Robert L Ferris
Journal:  Cancer Immunol Res       Date:  2018-10-03       Impact factor: 11.151

6.  A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice.

Authors:  Gabriela Maria Wiedemann; Severin Johannes Jacobi; Michael Chaloupka; Angelina Krächan; Svetlana Hamm; Stefan Strobl; Roland Baumgartner; Simon Rothenfusser; Peter Duewell; Stefan Endres; Sebastian Kobold
Journal:  Oncoimmunology       Date:  2016-05-31       Impact factor: 8.110

Review 7.  Tim-3, Lag-3, and TIGIT.

Authors:  Nicole Joller; Vijay K Kuchroo
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

Review 8.  Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.

Authors:  Ana C Anderson; Nicole Joller; Vijay K Kuchroo
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

9.  Secretory TRAIL-Armed Natural Killer Cell-Based Therapy: In Vitro and In Vivo Colorectal Peritoneal Carcinomatosis Xenograft.

Authors:  Xinxin Song; Se-Hoon Hong; William T Kwon; Lisa M Bailey; Per Basse; David L Bartlett; Yong Tae Kwon; Yong J Lee
Journal:  Mol Cancer Ther       Date:  2016-04-12       Impact factor: 6.261

10.  Recent Advances in Head and Neck Tumor Microenvironment-Based Therapy.

Authors:  Muzafar A Macha; Nissar A Wani; Rais A Ganai; Ajaz A Bhat; Abid Hamid; Sheema Hashem; Mohammad Haris; Sham S Chauhan; Mohammad A Zargar; Surinder K Batra
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.